Form 4: Roivant Sciences CEO Sells Shares for Tax Obligations

Roivant Sciences' President and Immunovant CEO, Eric Venker, disposed of 7,051 common shares at $27.15 each to cover tax withholding obligations related to RSU vesting.

Summary

• Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported a transaction involving company common shares.
• The transaction, dated February 20, 2026, involved the disposition of 7,051 common shares.
• The shares were disposed of at a price of $27.15 per share.
• This disposition was a 'net settlement' by Roivant Sciences to satisfy applicable tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• Following this transaction, Eric Venker beneficially owns 1,647,546 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine 'sell-to-cover' for tax purposes related to RSU vesting and does not indicate a change in management's outlook or a discretionary sale.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell-to-cover' event for tax purposes, which is common practice for executives receiving equity compensation. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disposition of a relatively small number of shares by an executive for tax purposes is a routine event and is unlikely to have a material impact on the company's stock price or long-term shareholder value.
• Employees: The transaction reflects standard equity compensation practices for executives.

Key Dates

Keywords

Roivant Sciences, ROIV, Eric Venker, Form 4, Insider Transaction, Share Disposition, RSU Vesting, Tax Withholding, Beneficial Ownership